Logo image of CME

CME GROUP INC (CME) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CME - US12572Q1058 - Common Stock

273.55 USD
+1.15 (+0.42%)
Last: 12/12/2025, 8:22:03 PM
273.55 USD
0 (0%)
After Hours: 12/12/2025, 8:22:03 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to CME. CME was compared to 237 industry peers in the Capital Markets industry. While CME belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. CME is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year CME was profitable.
In the past year CME had a positive cash flow from operations.
CME had positive earnings in each of the past 5 years.
CME had a positive operating cash flow in each of the past 5 years.
CME Yearly Net Income VS EBIT VS OCF VS FCFCME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1.2 Ratios

CME has a Return On Assets (1.99%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of 13.18%, CME is in the better half of the industry, outperforming 71.73% of the companies in the same industry.
CME has a better Return On Invested Capital (18.72%) than 95.78% of its industry peers.
CME had an Average Return On Invested Capital over the past 3 years of 15.81%. This is significantly above the industry average of 7.00%.
The last Return On Invested Capital (18.72%) for CME is above the 3 year average (15.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.99%
ROE 13.18%
ROIC 18.72%
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
CME Yearly ROA, ROE, ROICCME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

With a decent Profit Margin value of 32.91%, CME is doing good in the industry, outperforming 78.48% of the companies in the same industry.
In the last couple of years the Profit Margin of CME has declined.
Looking at the Operating Margin, with a value of 80.16%, CME belongs to the top of the industry, outperforming 98.73% of the companies in the same industry.
CME's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 80.16%
PM (TTM) 32.91%
GM N/A
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
CME Yearly Profit, Operating, Gross MarginsCME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80 100

5

2. Health

2.1 Basic Checks

CME has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CME has more shares outstanding
CME has a better debt/assets ratio than last year.
CME Yearly Shares OutstandingCME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CME Yearly Total Debt VS Total AssetsCME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

CME has a debt to FCF ratio of 0.84. This is a very positive value and a sign of high solvency as it would only need 0.84 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.84, CME belongs to the best of the industry, outperforming 89.45% of the companies in the same industry.
CME has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.12, CME is in the better half of the industry, outperforming 77.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.84
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CME Yearly LT Debt VS Equity VS FCFCME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

CME has a Current Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.02, CME is in line with its industry, outperforming 45.15% of the companies in the same industry.
CME has a Quick Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
CME has a Quick ratio of 1.02. This is comparable to the rest of the industry: CME outperforms 49.37% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
CME Yearly Current Assets VS Current LiabilitesCME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

5

3. Growth

3.1 Past

CME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.41%, which is quite good.
Measured over the past years, CME shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.57% on average per year.
Looking at the last year, CME shows a quite strong growth in Revenue. The Revenue has grown by 10.03% in the last year.
Measured over the past years, CME shows a quite strong growth in Revenue. The Revenue has been growing by 13.14% on average per year.
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%

3.2 Future

The Earnings Per Share is expected to grow by 7.30% on average over the next years.
CME is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.71% yearly.
EPS Next Y9.47%
EPS Next 2Y7.01%
EPS Next 3Y6.81%
EPS Next 5Y7.3%
Revenue Next Year5.94%
Revenue Next 2Y5.46%
Revenue Next 3Y5.53%
Revenue Next 5Y4.71%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CME Yearly Revenue VS EstimatesCME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B 10B
CME Yearly EPS VS EstimatesCME Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5 10

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 24.96 indicates a rather expensive valuation of CME.
Based on the Price/Earnings ratio, CME is valued a bit more expensive than the industry average as 65.82% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Earnings ratio of 26.56, CME is valued at the same level.
The Price/Forward Earnings ratio is 23.28, which indicates a rather expensive current valuation of CME.
CME's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. CME is more expensive than 61.60% of the companies in the same industry.
CME's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.79.
Industry RankSector Rank
PE 24.96
Fwd PE 23.28
CME Price Earnings VS Forward Price EarningsCME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CME indicates a rather cheap valuation: CME is cheaper than 87.76% of the companies listed in the same industry.
CME's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 24.15
EV/EBITDA 10.59
CME Per share dataCME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of CME may justify a higher PE ratio.
PEG (NY)2.64
PEG (5Y)2.91
EPS Next 2Y7.01%
EPS Next 3Y6.81%

5

5. Dividend

5.1 Amount

CME has a Yearly Dividend Yield of 1.84%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 6.13, CME has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.87, CME has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.84%

5.2 History

On average, the dividend of CME grows each year by 16.00%, which is quite nice.
CME has paid a dividend for at least 10 years, which is a reliable track record.
CME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
CME Yearly Dividends per shareCME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8 10

5.3 Sustainability

104.85% of the earnings are spent on dividend by CME. This is not a sustainable payout ratio.
CME's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP104.85%
EPS Next 2Y7.01%
EPS Next 3Y6.81%
CME Yearly Income VS Free CF VS DividendCME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B
CME Dividend Payout.CME Dividend Payout, showing the Payout Ratio.CME Dividend Payout.PayoutRetained Earnings

CME GROUP INC

NASDAQ:CME (12/12/2025, 8:22:03 PM)

After market: 273.55 0 (0%)

273.55

+1.15 (+0.42%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-22 2025-10-22/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners91.61%
Inst Owner Change0.46%
Ins Owners0.25%
Ins Owner Change2.41%
Market Cap98.64B
Revenue(TTM)11.29B
Net Income(TTM)3.72B
Analysts69.52
Price Target289.08 (5.68%)
Short Float %1.51%
Short Ratio2.86
Dividend
Industry RankSector Rank
Dividend Yield 1.84%
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP104.85%
Div Incr Years11
Div Non Decr Years11
Ex-Date12-12 2025-12-12 (1.25)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.59%
Min EPS beat(2)0.43%
Max EPS beat(2)0.76%
EPS beat(4)3
Avg EPS beat(4)0.49%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.72%
EPS beat(12)10
Avg EPS beat(12)0.95%
EPS beat(16)14
Avg EPS beat(16)1.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)7.34%
Revenue beat(16)7
Avg Revenue beat(16)10.88%
PT rev (1m)-0.49%
PT rev (3m)-0.49%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)-0.34%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-0.44%
Revenue NQ rev (1m)0.25%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-0.53%
Valuation
Industry RankSector Rank
PE 24.96
Fwd PE 23.28
P/S 8.73
P/FCF 24.15
P/OCF 23.71
P/B 3.5
P/tB N/A
EV/EBITDA 10.59
EPS(TTM)10.96
EY4.01%
EPS(NY)11.75
Fwd EY4.29%
FCF(TTM)11.33
FCFY4.14%
OCF(TTM)11.54
OCFY4.22%
SpS31.32
BVpS78.18
TBVpS-6.01
PEG (NY)2.64
PEG (5Y)2.91
Graham Number138.85
Profitability
Industry RankSector Rank
ROA 1.99%
ROE 13.18%
ROCE 24.11%
ROIC 18.72%
ROICexc 20.09%
ROICexgc 151.85%
OM 80.16%
PM (TTM) 32.91%
GM N/A
FCFM 36.16%
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
ROICexc(3y)17.24%
ROICexc(5y)12.98%
ROICexgc(3y)263.94%
ROICexgc(5y)202.43%
ROCE(3y)20.37%
ROCE(5y)15.39%
ROICexgc growth 3Y53.64%
ROICexgc growth 5Y25.03%
ROICexc growth 3Y41.34%
ROICexc growth 5Y22.06%
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.84
Debt/EBITDA 0.36
Cap/Depr 23.26%
Cap/Sales 0.68%
Interest Coverage 66.76
Cash Conversion 44.34%
Profit Quality 109.88%
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z N/A
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)29.97%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.86%
Profit Quality(3y)106.99%
Profit Quality(5y)105.5%
High Growth Momentum
Growth
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
EPS Next Y9.47%
EPS Next 2Y7.01%
EPS Next 3Y6.81%
EPS Next 5Y7.3%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
Revenue Next Year5.94%
Revenue Next 2Y5.46%
Revenue Next 3Y5.53%
Revenue Next 5Y4.71%
EBIT growth 1Y12.23%
EBIT growth 3Y39.48%
EBIT growth 5Y19.95%
EBIT Next Year11.96%
EBIT Next 3Y7.99%
EBIT Next 5Y7.1%
FCF growth 1Y23.34%
FCF growth 3Y16.49%
FCF growth 5Y8.18%
OCF growth 1Y22.71%
OCF growth 3Y15.38%
OCF growth 5Y6.67%

CME GROUP INC / CME FAQ

What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CME.


What is the valuation status for CME stock?

ChartMill assigns a valuation rating of 2 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.


Can you provide the profitability details for CME GROUP INC?

CME GROUP INC (CME) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for CME stock?

The Price/Earnings (PE) ratio for CME GROUP INC (CME) is 24.96 and the Price/Book (PB) ratio is 3.5.


How sustainable is the dividend of CME GROUP INC (CME) stock?

The dividend rating of CME GROUP INC (CME) is 5 / 10 and the dividend payout ratio is 104.85%.